Fluoguide Q4 2021: Calm Before the Storm - Redeye

Redeye comments on Fluoguide’s Q4 report, following a relatively calm couple of months on the news front. However, the company faces multiple potential catalysts during 2022, including high-grade glioma and NSCLC phase II readouts. The share has taken some beating recently, and we believe a lower share price and multiple upcoming catalysts could provide an attractive entry point.

Länk till analysen i sin helhet: https://www.redeye.se/research/837378/fluoguide-q4-2021-calm-before-the-storm?utm_source=finwire&utm_medium=RSS